Deep in the prefrontal cortex — the brain region responsible for planning, decision-making, and impulse control — sits a receptor that helps determine how you respond to novelty, risk, and reward. The dopamine D4 receptor¹¹ dopamine D4 receptor
One of five dopamine receptor subtypes (D1-D5). D4 is unusual because it's concentrated in the prefrontal cortex rather than the striatum, giving it an outsized role in higher cognitive functions like attention, working memory, and behavioral flexibility is encoded by the DRD4 gene, and its promoter variant²² promoter variant
A variant in the regulatory region upstream of the gene that controls how much of the gene is transcribed into mRNA, and ultimately into protein rs1800955 (-521C>T) determines how many of these receptors your brain produces.

The DRD4 gene is perhaps best known for its exon 3 VNTR³³ exon 3 VNTR
A variable number tandem repeat (VNTR) where a 48-base-pair sequence is repeated 2-11 times. The 7-repeat (7R) allele has been widely associated with ADHD and novelty seeking, but it is NOT detectable on SNP chips, a repeat-length polymorphism that cannot be measured by SNP chips. The -521C>T promoter variant is the best chip-genotypable proxy for DRD4 functional variation, and it has its own well-documented effects on gene expression and behavior.

The Mechanism

The -521C>T variant sits 521 base pairs upstream of the DRD4 transcription start site, squarely in the gene's core promoter. Okuyama et al.⁴⁴ Okuyama et al.
Okuyama Y et al. A genetic polymorphism in the promoter region of DRD4 associated with expression and schizophrenia. Biochem Biophys Res Commun, 1999 used transient expression assays to show that the C allele drives approximately 40% higher transcriptional activity than the T allele. More D4 receptors in the prefrontal cortex means greater sensitivity to dopamine signaling in circuits that govern attention, behavioral flexibility, and reward processing.

It is worth noting that a later study⁵⁵ later study
D'Souza UM et al. No direct effect of the -521 C/T polymorphism in the human dopamine D4 receptor gene promoter on transcriptional activity. BMC Mol Biol, 2006 did not replicate the direct transcriptional effect, suggesting the functional mechanism may involve linkage disequilibrium with other nearby regulatory variants rather than the -521 position alone. Regardless of the precise molecular mechanism, the behavioral associations with this marker are well replicated.

The Evidence

The strongest evidence for rs1800955 comes from personality and behavioral genetics. Okuyama et al.⁶⁶ Okuyama et al.
Okuyama Y et al. Identification of a polymorphism in the promoter region of DRD4 associated with the human novelty seeking personality trait. Mol Psychiatry, 2000 first reported that CC carriers scored highest on novelty seeking (P=0.0001) in 86 healthy Japanese volunteers, with TT carriers scoring lowest. A meta-analysis by Munafò et al.⁷⁷ meta-analysis by Munafò et al.
Munafò MR et al. Association of the dopamine D4 receptor (DRD4) gene and approach-related personality traits: meta-analysis and new data. Biol Psychiatry, 2008 confirmed the association with novelty seeking and impulsivity (though not extraversion), estimating the C allele accounts for up to 3% of phenotypic variance — small by individual-gene standards, but among the larger effects in personality genetics.

The clinical implications extend to psychiatric risk. A meta-analysis of schizophrenia studies⁸⁸ meta-analysis of schizophrenia studies
Mou L et al. A meta-analysis of data associating DRD4 gene polymorphisms with schizophrenia. Neuropsychiatr Dis Treat, 2018 pooling 2,927 cases and 2,938 controls found the CC genotype confers modestly elevated schizophrenia risk (OR 1.22, 95% CI 1.05–1.41, P=0.009). This aligns with the dopamine hypothesis of schizophrenia⁹⁹ dopamine hypothesis of schizophrenia
The longstanding theory that excessive dopamine signaling in certain brain pathways contributes to psychotic symptoms. Antipsychotic medications work primarily by blocking dopamine D2 receptors, where heightened dopaminergic tone may increase vulnerability.

On the positive side, Gilman et al.¹⁰¹⁰ Gilman et al.
Gilman TL et al. DRD4 polymorphism associated with greater positive affect in response to negative and neutral social stimuli. Ann Hum Genet, 2022 found that CC carriers maintain higher positive affect during negative and neutral social stimuli across two independent samples (N=120 and N=122) — suggesting emotional resilience or a "rose-tinted glasses" effect that may underlie the novelty-seeking phenotype.

The sensation-seeking association extends to real-world behavior: Thomson et al.¹¹¹¹ Thomson et al.
Thomson CJ et al. The -521 C/T variant in the dopamine-4-receptor gene (DRD4) is associated with skiing and snowboarding behavior. Scand J Med Sci Sports, 2013 found CC genotype was significantly associated with sports-specific sensation seeking in 503 experienced skiers and snowboarders (P<0.001).

Practical Implications

This is fundamentally a personality-influencing variant, not a disease-causing one. The C allele tilts you toward novelty seeking, risk tolerance, and cognitive flexibility — traits that can be assets or liabilities depending on context. The key is awareness: understanding your dopaminergic tendency helps you harness its strengths (creativity, adaptability, positive outlook) while managing its downsides (impulsivity, difficulty with routine tasks, risk-taking).

For CC carriers, structured approaches to decision-making can counterbalance impulsive tendencies. Mindfulness practice has been shown to strengthen prefrontal regulation of dopaminergic circuits. Regular physical exercise, particularly aerobic exercise, helps regulate dopamine levels naturally.

For TT carriers, the lower D4 receptor expression means a more methodical, risk-averse cognitive style. While this can mean missing out on spontaneous opportunities, it also provides natural protection against impulsive decision-making. TT carriers may benefit from deliberately seeking out novel experiences to maintain cognitive flexibility.

Interactions

The most documented interaction is with COMT (rs4680), which controls dopamine degradation in the prefrontal cortex. Alfimova et al.¹²¹² Alfimova et al.
Alfimova MV et al. Interaction of dopamine system genes and cognitive functions in patients with schizophrenia and their relatives and in healthy subjects from the general population. Neurosci Behav Physiol, 2007 found that the DRD4 -521C/T and COMT Val158Met genotypes interact to affect verbal fluency and working memory. The combination of CC (high D4 expression) with COMT Met/Met (slow dopamine clearance) creates the highest prefrontal dopamine tone — potentially enhancing creative thinking but also increasing vulnerability to overstimulation. Conversely, COMT Val/Val (fast clearance) combined with TT (low D4 expression) produces the lowest prefrontal dopamine signaling.

DRD4 also interacts with the broader dopamine signaling pathway. Other DRD4 variants (including the exon 3 VNTR and the nearby rs747302 promoter variant) can modify the functional impact of -521C/T, though these interactions are less well characterized for chip-genotypable SNPs.

Every arterial wall, every lens zonule, every ligament that holds your skeleton together depends on a microscopic scaffolding called the microfibril¹¹ microfibril
a rope-like structure in the extracellular matrix assembled from fibrillin-1 molecules end-to-end, providing elasticity and tensile strength to connective tissue throughout the body. Fibrillin-1 is encoded by FBN1 — a 66-exon gene on chromosome 15 producing a 2,871-amino-acid glycoprotein studded with 47 epidermal growth factor-like (EGF-like) domains. Forty-three of these domains are calcium-binding (cbEGF), and calcium ions are essential to their structural rigidity. A single amino acid substitution in any one of these domains can be enough to compromise the entire fibrillin polymer.

The p.Gly2627Arg substitution — coded by two different nucleotide changes at the same genomic position (NC_000015.10:g.48415708C>G or C>T, both producing the same coding-strand change c.7879G>C or c.7879G>A on the minus-strand FBN1 transcript) — replaces a small, flexible glycine with a bulky, positively charged arginine at position 2627 of fibrillin-1. This position sits within a cbEGF-like domain in the C-terminal half of the protein. ClinVar classifies this variant as Pathogenic/Likely Pathogenic with multiple independent submissions²² Pathogenic/Likely Pathogenic with multiple independent submissions
ClinVar VCV000372606, criteria provided, multiple submitters, no conflicts, including a 2025 Pathogenic classification from Labcorp Genetics/Invitae. The variant is essentially absent from population databases (not detected in ALFA across

187,000 alleles), consistent with its role as a rare, high-penetrance disease allele.

The Mechanism

Glycine residues in EGF-like domains serve as structural pivots³³ Glycine residues in EGF-like domains serve as structural pivots
glycine's side chain is a single hydrogen atom, making it uniquely suited for tight turns and compact folds that other amino acids cannot achieve. Substituting glycine with arginine introduces a large, charged side chain that distorts the calcium-binding loop. When calcium fails to bind correctly, the cbEGF domain cannot fold into its normal rigid rod-like conformation. This locally misfolded domain then disrupts the folding of adjacent domains through a propagation effect, ultimately destabilizing the entire fibrillin-1 monomer. Abnormal fibrillin-1 impairs microfibril polymerization through a dominant-negative mechanism⁴⁴ dominant-negative mechanism
the defective monomer interferes with the assembly of normal monomers into functional microfibrils, so even one mutant copy disrupts the whole network, explaining why a single heterozygous copy is sufficient to cause disease.

Beyond structural weakness, impaired fibrillin-1 microfibrils fail to sequester transforming growth factor-beta (TGF-β) in the extracellular matrix. Excessive free TGF-β signaling drives aortic smooth muscle cell dysfunction, progressive aortic wall stiffening, and the aneurysmal dilatation that is the leading cause of premature death in Marfan syndrome.

The Evidence

Dietz et al. (Genomics, 1993)⁵⁵ Dietz et al. (Genomics, 1993) established that all known FBN1 missense mutations causing classic Marfan syndrome at that time fell at residues with calcium-binding significance in EGF-like domains — the same structural domain affected by Gly2627Arg. The clinical phenotype associated with cbEGF missense mutations is consistently severe, including cardiovascular, ocular, and skeletal manifestations.

The most important clinical outcome data come from the French Marfan cohort followed by Milleron et al. (JACC, 2020)⁶⁶ Milleron et al. (JACC, 2020): 954 patients with FBN1 pathogenic variants followed over 8,594 patient-years showed that type A aortic dissection occurred at only 0.4 events per 1,000 patient-years when the maximal aortic diameter remained below 50 mm with guideline-directed treatment (beta-blockers, exercise restriction). The key message: risk is manageable when diagnosed early and monitored diligently.

On the treatment side, Brooke et al. (N Engl J Med, 2008)⁷⁷ Brooke et al. (N Engl J Med, 2008) demonstrated that the angiotensin receptor blocker losartan reduced aortic root dilation rate from 3.54 mm/yr to 0.46 mm/yr in 18 pediatric Marfan patients — an approximately 87% reduction — by blocking TGF-β pathway activation. This finding underpins the current guideline recommendation to add an ARB if aortic progression rate exceeds 5 mm/year or root diameter exceeds 40 mm in children.

Practical Actions

FBN1 pathogenic variant carriers require structured, lifelong cardiac surveillance. Annual transthoracic echocardiography is the standard; cardiac MRI can be added for improved accuracy, especially at the aortic sinuses and ascending aorta. Medical therapy with a beta-blocker or ARB (commonly losartan) reduces hemodynamic stress on the aortic wall and should be initiated at diagnosis or upon confirming progressive dilation. Prophylactic aortic root surgery is recommended when the root approaches 5.0 cm in adults or progresses rapidly regardless of absolute diameter.

Fluoroquinolone antibiotics (ciprofloxacin, levofloxacin, moxifloxacin) are contraindicated for this genotype — they inhibit lysyl oxidase, the enzyme responsible for cross-linking collagen and elastin, and have been linked to aortic aneurysm rupture and dissection in connective tissue disorder patients. Decongestants and vasoconstrictors (including nasal decongestants, triptans for migraine) should be used only under medical supervision given their effects on aortic wall stress.

Annual ophthalmologic examination is also indicated: approximately 60% of Marfan patients develop ectopia lentis (lens dislocation) and are at elevated risk for retinal detachment and glaucoma.

Interactions

The dominant-negative mechanism of FBN1 missense mutations means that second-hit variants in fibrillin-1 or in related extracellular matrix genes are unlikely (two pathogenic FBN1 alleles causes a severe neonatal Marfan phenotype that is not typically compatible with adulthood). However, modifier effects in TGF-β pathway genes (TGFBR1, TGFBR2, SMAD2, SMAD3) have been described in related connective tissue disorders — Loeys-Dietz syndrome — and may influence phenotypic severity in FBN1 carriers. Carriers who also have variants in ACTA2 or MYH11 (smooth muscle genes associated with familial thoracic aortic aneurysm) may warrant more aggressive surveillance thresholds, though formal compound genotype data for this specific FBN1 variant are not published.

The melanocortin-4 receptor (MC4R) gene is the best-characterized monogenic and polygenic obesity locus known. Hypothalamic MC4R neurons sit at the convergence of leptin and melanocortin signaling: when fat stores are adequate, POMC neurons release alpha-MSH, which binds MC4R to suppress appetite and raise energy expenditure. Disrupting this pathway — by coding mutations, copy-number variants, or regulatory variants that reduce receptor expression — leads to increased food intake and fat deposition. rs1943226 sits approximately 3 kilobases upstream of the MC4R transcription start site¹¹ 3 kilobases upstream of the MC4R transcription start site
at chr18:60,367,971 GRCh38, with MC4R running from 60,371,062 to 60,372,775 on the minus strand.

This is a haplotype depth variant. GeneOps already covers rs17782313²² rs17782313
the primary MC4R-region obesity GWAS signal (~188kb downstream), replicated across >100,000 participants and rs12970134³³ rs12970134
the discovery-paper waist circumference signal, p=1.7×10⁻⁹ in Indian Asians and Europeans. rs1943226 was included as a third MC4R tagSNP in a Belgian association study alongside those two, and appears in the GWAS Catalog with a BMI association at p=1×10⁻²⁶ — a large signal driven by its position in the same extended MC4R haplotype block.

The Mechanism

The MC4R gene is transcribed on the minus strand; the region just upstream on the plus strand contains regulatory DNA including the proximal promoter and early enhancer elements. rs1943226 (T>G substitution, plus strand) lies approximately 3kb upstream of the MC4R start codon, within the zone where transcription factor binding and chromatin accessibility directly influence receptor expression in hypothalamic neurons.

No functional molecular study has been published specifically for rs1943226. No electrophoretic mobility-shift assay, luciferase reporter, chromatin immunoprecipitation, or eQTL data has been reported for this variant. It is classified as a regulatory or intronic variant⁴⁴ classified as a regulatory or intronic variant
Ensembl VEP classifies it as affecting a nearby transcript at position n.156+38626, with low CADD scores of 0.42 (C) and 0.38 (G), indicating minimal predicted functional impact rather than a functionally characterized regulatory element. It is more accurately understood as a genomic marker that co-segregates with the MC4R haplotype block than as a variant with established independent molecular function.

The Evidence

The most direct evidence comes from Beckers et al. (2011)⁵⁵ Beckers et al. (2011)
Association study of MC4R with complex obesity in 1,049 obese Belgians vs. 312 lean controls. The authors selected rs1943226 as one of three MC4R tagSNPs (alongside rs8087522 and rs11872992) to fully capture haplotype diversity at the MC4R locus. Their results were unambiguous: "No associations with obesity could be found for rs8087522 and rs1943226." At the same time, rs17782313 replicated strongly (OR=1.42, 95% CI 1.14–1.77, p=0.002), confirming the study had adequate power to detect real MC4R-region effects. The negative result for rs1943226 indicates it does not carry independent disease-mapping information beyond what rs17782313 already captures in European ancestry.

The large GWAS signal (p=1×10⁻²⁶ for BMI) recorded in the GWAS Catalog from Zhu et al. (2020)⁶⁶ Zhu et al. (2020)
UK Biobank cross-trait analysis of obesity-asthma shared genetics is almost certainly a tag signal⁷⁷ tag signal
a statistical association inherited from nearby causal variants through linkage disequilibrium rather than evidence that rs1943226 is itself causal. The effect size was not separately reported for this SNP, and the paper identified the MC4R locus collectively as a shared obesity-asthma locus without attributing causality to this specific marker.

Practical Implications

For individuals carrying the G allele at rs1943226, the main value is as a haplotype indicator. A G allele at this position marks co-occurrence with the same extended MC4R regulatory region that overlaps rs17782313 and rs12970134. If those primary variants are also present, their associated advice (waist circumference monitoring, insulin resistance awareness, structured meal timing) applies. The rs1943226 G allele adds depth to the haplotype picture but does not independently change the clinical recommendation set beyond what the primary MC4R variants already indicate.

The South Asian population carries the highest G-allele frequency at ~13.6% (vs. ~8.9% European, ~1.5% African, ~0% East Asian), consistent with the broader MC4R locus showing stronger signals for central adiposity in South Asian populations, where waist circumference risk is often more clinically relevant than BMI alone.

Interactions

rs17782313 and rs12970134: These are the primary functional signals at the MC4R locus. rs1943226 was explicitly tested in studies alongside them and found to carry no independent association. The three variants tag different aspects of the same haplotype block; if rs17782313 or rs12970134 risk alleles are present, those entries contain the actionable recommendations for MC4R-related adiposity and insulin resistance.

rs8087522: The Beckers 2011 study found no obesity association for rs8087522 and rs1943226 in the same analysis, suggesting they tag similar null-effect haplotypes at the proximal MC4R upstream region. rs8087522 has a separate signal in antipsychotic-induced weight gain through proposed transcription factor binding site creation; whether rs1943226 shares that pharmacogenomic signal has not been studied.

Estrogen receptor alpha (ERα), encoded by ESR1, is the master mediator of estrogen's effects on reproductive tissue. It sits in the nucleus of endometrial, breast, and uterine cells, waiting for estrogen to arrive — and when it does, it binds estrogen and turns on hundreds of downstream genes controlling cell growth, differentiation, and inflammation. Getting the amount of ERα right matters enormously: too much, and tissues become hypersensitive to estrogen, proliferating when they shouldn't.

rs2046210 sits in the promoter region¹¹ promoter region
A promoter is a DNA region immediately upstream of a gene where transcription machinery binds to start copying the gene into RNA approximately 29 kilobases upstream of the ESR1 transcription start site, between the C6orf97/CCDC170 gene and ESR1 itself. The A allele alters the chromatin environment at this locus in a way that increases baseline ESR1 transcription — meaning cells that carry the A allele simply produce more estrogen receptor protein, making the entire estrogen-signaling axis more reactive.

The Mechanism

The variant was discovered in a genome-wide association study of Chinese women²² genome-wide association study of Chinese women
Zheng et al. Nature Genetics, 2009 and confirmed as a regulatory locus by eQTL (expression quantitative trait locus) analyses showing that risk-allele carriers have statistically higher expression of ESR1 in adjacent normal breast tissue (P = 0.04) and in the eutopic endometrium of women with endometriosis. Functional studies³³ Functional studies
Sun et al. Carcinogenesis, 2016 also implicate the nearby AKAP12 gene, whose expression correlates with rs2046210 genotype in the same tissue samples (P = 0.02). The net effect is a constitutively elevated estrogen-sensing state in sensitive reproductive tissues, which predisposes to estrogen-driven proliferative conditions.

For endometriosis specifically, the mechanism is particularly direct: elevated ERα in ectopic endometrial-like lesions amplifies their response to circulating estrogen, promoting growth, survival, and inflammatory signaling in lesions implanted on peritoneal surfaces, ovaries, and pelvic ligaments. A 2024 Austrian case-control study⁴⁴ A 2024 Austrian case-control study
Proestling et al. Biomedicines, 2024 found significantly increased ESR1 expression in eutopic endometrium of women with endometriosis who carried the GA genotype — confirming the mechanistic link between the rs2046210 risk allele and enhanced estrogen receptor signaling in affected tissue.

The Evidence

The breast cancer data is the most statistically robust due to sample size. The discovery GWAS by Zheng et al. (2009)⁵⁵ Zheng et al. (2009)
Nature Genetics; 1,505 cases and 1,522 controls in Chinese women with two independent replication cohorts identified rs2046210 as genome-wide significant (P = 2.0 × 10⁻¹⁵). The odds ratios were 1.36 (95% CI 1.24–1.49) for heterozygotes (AG) and 1.59 (95% CI 1.40–1.82) for homozygotes (AA) compared to GG. These numbers were confirmed across >31,000 women in Chinese, Japanese, and European populations by Cai et al. (2011)⁶⁶ Cai et al. (2011)
Cancer Research, and further consolidated in a meta-analysis of 235,003 subjects (13 studies)⁷⁷ meta-analysis of 235,003 subjects (13 studies)
Wu et al. PLoS One, 2013 showing per-allele OR 1.13 (95% CI 1.10–1.17). A larger meta-analysis of 121,494 cases and 119,295 controls (14 studies)⁸⁸ 121,494 cases and 119,295 controls (14 studies)
Yang et al. Breast Cancer Research and Treatment, 2013 replicated the A allele association with OR 1.16 (95% CI 1.11–1.21).

The endometriosis evidence is more recent and from smaller studies. The 2024 Proestling et al. paper is the first to directly link rs2046210 to endometriosis risk and elevated ESR1 expression in endometrial tissue, with the GA genotype driving the association particularly in younger, leaner, and infertile women — the classic endometriosis clinical profile. The endometrial cancer association, shown in a Chinese population-based study (OR 1.28 in postmenopausal women), provides corroborating evidence that the locus broadly sensitizes estrogen-responsive gynecological tissue.

The risk conferred by a single common variant of this effect size is moderate on an individual level — an OR of 1.36 for heterozygotes means roughly 36% higher relative risk compared to GG, which, against a population endometriosis prevalence of ~10%, translates to an absolute shift of a few percentage points. It is more meaningful as a biological signal — pointing to estrogen receptor upregulation as a mechanism — than as a standalone clinical predictor.

Practical Actions

The clinical implication of elevated ESR1 expression is heightened sensitivity to estrogen. Interventions that modulate estrogen bioavailability — either by reducing exposure or supporting efficient estrogen metabolism — are especially relevant for risk-allele carriers.

For endometriosis specifically, the combination of elevated estrogen sensitivity and the high diagnostic delay (4–11 years on average) argues for proactive symptom recognition and early specialist evaluation. Risk-allele carriers who have gynecological symptoms consistent with endometriosis should request specialist evaluation rather than accept normalization of pain.

Dietary indole-3-carbinol (I3C) from cruciferous vegetables promotes 2-hydroxylation of estradiol via CYP1A1/CYP1A2, shifting metabolism toward the less proliferative 2-OH pathway and away from 16-α-OH estrone, which has been shown to reduce estrogenic proliferative signaling in endometrial and breast tissue. This is particularly relevant when ESR1 expression is constitutively elevated.

Interactions

rs12700667 (7p15.2 / HOXA10-HOXA11 locus): The 7p15.2 locus is one of the strongest replicated endometriosis GWAS signals. Carrying risk alleles at both rs2046210 (increased ESR1 expression) and rs12700667 (altered HOX gene regulation affecting endometrial development) represents two mechanistically distinct pathways converging on endometriosis susceptibility — one increasing estrogen sensitivity, the other impairing normal endometrial patterning. Women carrying risk alleles at both loci may represent a subgroup with meaningfully higher cumulative endometriosis risk. Combined recommendation: earlier gynecological evaluation, proactive fertility workup, and lower threshold for diagnostic laparoscopy. Evidence level: moderate (both loci well-replicated; interaction testing not formally published).

rs9383590 (ESR1 coding region): rs9383590 is a coding-region ESR1 variant studied alongside rs2046210 in breast cancer. Both showed independent effects on breast cancer age at onset in the Miedl et al. (2023) study, with minor homozygotes presenting years earlier than common homozygotes in ER-positive and luminal cancers. Compound effects of rs2046210 (upstream regulatory) and rs9383590 (coding/functional) on ESR1 activity have not been formally tested in endometriosis.

Your gut hosts trillions of bacteria, and your immune system must constantly distinguish friend from foe. The NOD2 gene encodes an intracellular bacterial sensor¹¹ intracellular bacterial sensor
NOD2 (nucleotide-binding oligomerization domain-containing protein 2) recognizes muramyl dipeptide (MDP), a component of bacterial cell walls that acts as a pattern-recognition receptor for bacterial peptidoglycans. When functioning normally, NOD2 helps maintain homeostasis in the gut²² homeostasis in the gut
balancing inflammatory and anti-inflammatory responses to commensal bacteria by modulating immune responses and regulating the composition of gut microbiota, particularly in the small intestine.

The R702W variant was among the first genetic risk factors discovered for Crohn's disease³³ first genetic risk factors discovered for Crohn's disease
identified in 2001 through linkage studies on chromosome 16 and remains the single strongest genetic predictor of this inflammatory bowel disease. This missense mutation changes arginine to tryptophan at position 702 in the leucine-rich repeat (LRR) domain, the part of the protein responsible for recognizing bacterial molecules.

The Mechanism

The R702W substitution occurs in the leucine-rich repeat domain⁴⁴ leucine-rich repeat domain
this domain recognizes muramyl dipeptide from bacterial peptidoglycan of the NOD2 protein, altering its ability to sense and respond to bacterial components. Unlike the more severe L1007fs frameshift mutation, R702W results in a partial loss of function⁵⁵ partial loss of function
retains some ability to activate NF-κB but with reduced efficiency rather than complete protein truncation. Studies show that R702W impairs the protein's ability to detect muramyl dipeptide and downregulate excessive TLR responses⁶⁶ downregulate excessive TLR responses
NOD2 normally suppresses Toll-like receptor signaling to prevent overreaction to gut bacteria.

NOD2 is highly expressed in ileal Paneth cells⁷⁷ highly expressed in ileal Paneth cells
specialized epithelial cells in the small intestine that secrete antimicrobial peptides, which produce antimicrobial defensins to regulate the bacterial load in the terminal ileum. The R702W variant is associated with reduced defensin production⁸⁸ reduced defensin production
though this may result from chronic inflammation rather than direct genetic effect, allowing increased colonization by potentially inflammatory bacterial species and creating a dysbiotic state that predisposes to intestinal inflammation.

The Evidence

A landmark meta-analysis of 75 case-control studies⁹⁹ A landmark meta-analysis of 75 case-control studies
18,727 Crohn's disease cases and 17,102 controls across multiple populations established that R702W carriers (CT genotype) have an odds ratio of 2.2 (95% CI 2.0-2.5) for developing Crohn's disease compared to non-carriers. The risk escalates dramatically with gene dosage¹⁰¹⁰ gene dosage
effect is codominant with increasing risk per copy of the risk allele: simple heterozygotes (one R702W) show 2.4-fold risk, while compound heterozygotes (R702W plus another NOD2 variant) have 9-fold risk and homozygotes (two R702W) reach 6.7-fold risk.

The variant shows strong genotype-phenotype correlation¹¹¹¹ strong genotype-phenotype correlation
R702W particularly predicts ileal disease location and stricturing behavior. A Finnish CD cohort found ileal involvement in 90% of NOD2 variant carriers versus 73% of non-carriers (p<0.05), and stricturing or penetrating disease occurred in 88% versus 56% (p<0.01). The R702W variant specifically associates with ileal-predominant disease¹²¹² ileal-predominant disease
the terminal ileum is where Paneth cells expressing NOD2 are most abundant, with mutation frequency of 26.9% in ileal CD versus 12.7% in colonic CD.

Geographic variation is striking¹³¹³ Geographic variation is striking
R702W is virtually absent in Asian populations but common in Europeans. In European CD cohorts, the R702W allele frequency reaches 10%, compared to essentially 0% in Japanese and Chinese populations where Crohn's disease has different genetic architecture. This suggests population-specific disease mechanisms¹⁴¹⁴ population-specific disease mechanisms
environmental factors and other genetic pathways drive CD in non-European populations.

Recent studies have revealed a recessive inheritance pattern¹⁵¹⁵ recessive inheritance pattern
biallelic NOD2 variants act as single-gene cause in subset of patients for a subset of Crohn's disease patients. Approximately 8% of pediatric-onset IBD patients carry two NOD2 risk alleles (either homozygous or compound heterozygous), and these patients show a markedly severe phenotype with 11.5-fold increased risk of stricturing disease¹⁶¹⁶ 11.5-fold increased risk of stricturing disease
compared to patients without NOD2 mutations requiring surgical intervention.

Practical Implications

If you carry one or two copies of R702W, your lifetime risk of developing Crohn's disease is elevated but penetrance remains low¹⁷¹⁷ penetrance remains low
even two-mutation carriers have less than 10% lifetime risk. The majority of R702W carriers never develop IBD, indicating that environmental triggers and additional genetic factors are required. However, understanding your genotype allows proactive gut health strategies¹⁸¹⁸ proactive gut health strategies
microbiome modulation and early symptom monitoring.

The gut microbiome plays a central role. Studies show NOD2-deficient mice have increased bacterial load¹⁹¹⁹ NOD2-deficient mice have increased bacterial load
particularly in the ileum where NOD2 is highly expressed and altered microbial composition, with decreased beneficial Firmicutes²⁰²⁰ decreased beneficial Firmicutes
including butyrate-producing species like Faecalibacterium prausnitzii and increased potentially inflammatory Enterobacteriaceae. Probiotic supplementation, particularly with Lactobacillus strains producing DL-endopeptidase²¹²¹ Lactobacillus strains producing DL-endopeptidase
this enzyme generates muramyl dipeptide that can stimulate residual NOD2 function, has shown promise in mouse models of colitis.

For heterozygous carriers (CT), focus on maintaining gut barrier integrity and microbial diversity through fiber-rich diet²²²² fiber-rich diet
feeds beneficial bacteria that produce short-chain fatty acids and judicious antibiotic use. For compound heterozygotes or homozygotes (those with two NOD2 risk alleles), more vigilant monitoring is warranted given the substantially elevated risk of complicated disease²³²³ substantially elevated risk of complicated disease
including strictures and fistulas requiring surgery.

Interactions

R702W commonly co-occurs with other NOD2 variants, particularly rs2066845 (G908R) and rs2066847 (L1007fs)²⁴²⁴ rs2066845 (G908R) and rs2066847 (L1007fs)
the three major CD-associated NOD2 mutations, creating compound heterozygotes with dramatically elevated risk. When an individual carries R702W on one chromosome and either G908R or L1007fs on the other, the combined effect produces a 9-fold increased risk of Crohn's disease²⁵²⁵ 9-fold increased risk of Crohn's disease
compared to 2-3-fold for single heterozygotes, with 98% specificity for complicated, stricturing disease requiring surgery.

NOD2 also interacts with ATG16L1 (rs2241880)²⁶²⁶ ATG16L1 (rs2241880)
another major CD risk gene involved in autophagy, a cellular process for degrading intracellular bacteria. NOD2 recruits ATG16L1 to sites of bacterial entry, and variants in both genes synergistically impair the intestinal epithelial response to bacterial invasion. Patients carrying risk variants in both NOD2 and ATG16L1 show additive risk beyond either variant alone²⁷²⁷ additive risk beyond either variant alone
suggesting convergent pathways in CD pathogenesis.

The interaction between NOD2 genotype and smoking is complex and counterintuitive²⁸²⁸ smoking is complex and counterintuitive
shows negative interaction with protective effect. While smoking increases CD risk in the general population, a case-only study found R702W carriers who smoke have lower risk than expected (OR 0.71, p=0.005), suggesting the genetic and environmental factors may operate through different mechanisms²⁹²⁹ genetic and environmental factors may operate through different mechanisms
biological interaction between NOD2 pathway and smoking-induced changes in gut immunity.

TMPRSS6¹¹ TMPRSS6
Transmembrane serine protease 6, also called matriptase-2 — a type II transmembrane serine protease expressed predominantly in the liver, whose key function is to cleave hemojuvelin from hepatocyte surfaces and thereby suppress hepcidin production is the body's primary brake on the iron-regulatory hormone hepcidin²² hepcidin
A 25-amino-acid peptide produced by the liver that controls iron homeostasis by targeting ferroportin, the sole iron export channel on gut enterocytes and macrophages, for degradation. Common TMPRSS6 variants consistently rank among the strongest genetic determinants of serum iron, transferrin saturation, and hemoglobin in genome-wide association studies across diverse populations.

rs2235321 sits in exon 15 of TMPRSS6 at chromosome 22q12.3. The G-to-A change on the plus strand corresponds to a synonymous substitution in the coding sequence — both codons encode tyrosine at position 730 (TAC→TAT, p.Tyr730=). Because the amino acid is unchanged, rs2235321 is not itself the functional variant. Instead, it acts as a haplotype tag³³ haplotype tag
A variant in linkage disequilibrium with one or more nearby functional variants; its alleles reliably predict which haplotype a chromosome belongs to even though the tag variant itself may have no direct functional effect, marking a haplotype that carries altered TMPRSS6 regulatory or splicing activity at a nearby position. The downstream consequence — measured directly in human studies — is a difference in circulating hepcidin levels between GG and AA homozygotes.

The Mechanism

Because rs2235321 is synonymous at the protein level, its association with hepcidin must be mediated through linkage with a nearby functional variant — one that influences TMPRSS6 expression level, mRNA splicing efficiency, or a second coding position in partial LD. Whatever the functional driver, the biological consequence fits the established TMPRSS6–hepcidin–iron axis: the G allele tags reduced effective matriptase-2 activity, leaving more hemojuvelin⁴⁴ hemojuvelin
A GPI-anchored co-receptor that amplifies BMP/SMAD signaling in hepatocytes, driving hepcidin transcription when intact on the cell surface; matriptase-2 cleaves it to dampen this pathway intact on hepatocyte surfaces. More intact hemojuvelin amplifies the BMP/SMAD signaling pathway⁵⁵ BMP/SMAD signaling pathway
Bone morphogenetic protein receptor / SMAD transcription factor cascade that is the primary positive regulator of hepcidin gene expression in the liver, driving hepcidin up. Higher hepcidin degrades ferroportin on duodenal enterocytes and recycling macrophages, tightening the outflow of iron into the bloodstream.

The A allele, by contrast, tags a haplotype with relatively higher matriptase-2 activity: more hemojuvelin is cleaved, BMP/SMAD signaling is damped, hepcidin production falls, and iron absorption and recycling improve.

The Evidence

Two complementary studies from the same Gambian research group provide the primary evidence for rs2235321's association with hepcidin.

A recall-by-genotype study⁶⁶ recall-by-genotype study
Jallow MW et al. Common Variants in the TMPRSS6 Gene Alter Hepcidin but not Plasma Iron in Response to Oral Iron in Healthy Gambian Adults. Curr Dev Nutr, 2021 recruited 80 healthy adults stratified by TMPRSS6 genotype and administered a single oral dose of ferrous sulfate (130 mg elemental iron). At baseline, GG homozygotes had significantly higher plasma hepcidin than AA homozygotes (9.50 vs 6.60 ng/mL, P = 0.035) — a 44% difference. The G allele showed a clear additive dose-response, with heterozygotes (AG) intermediate between the two homozygote groups.

A larger cross-sectional analysis⁷⁷ larger cross-sectional analysis
Jallow MW et al. Association of common TMPRSS6 and TF gene variants with hepcidin and iron status in healthy rural Gambians. Sci Rep, 2021 in 1,316 healthy Gambians confirmed the association: rs2235321 significantly affected plasma hepcidin concentrations (AA genotype having lower hepcidin; F = 3.7, P = 0.014). Notably, rs2235321 was the only TMPRSS6 variant in that cohort that independently affected hepcidin — neither rs855791 nor other genotyped TMPRSS6 variants reached significance for hepcidin in this African population, suggesting rs2235321 tags a distinct functional element at the TMPRSS6 locus that is informative beyond the primary Ala736Val coding variant.

In a prospective pregnancy cohort⁸⁸ prospective pregnancy cohort
Hayashi I et al. Association of a pro-inflammatory diet and gestational diabetes mellitus with maternal anemia and hemoglobin levels during pregnancy. Nutr Res, 2023, rs2235321 was associated with hemoglobin levels during the third trimester — a period of high iron demand when even modest absorption inefficiencies become clinically relevant.

ClinVar classifies this variant as benign, reflecting that it does not cause Mendelian disease on its own. The iron-status effects are modest, population-wide, and relevant primarily under conditions of increased iron demand rather than in nutritionally adequate populations. The evidence level is rated moderate: the hepcidin association is replicated across two independent analyses in African adults, with pregnancy-cohort replication in a separate population, but large-scale multi-ethnic conditional GWAS data specifically for hepcidin remain limited.

Practical Actions

The practical relevance of rs2235321 scales with iron demand. Under conditions of adequate dietary iron and no additional stressors, even GG homozygotes typically maintain normal hemoglobin. The gap between GG and AA becomes meaningful when iron demand is chronically elevated: heavy menstrual cycles, pregnancy, regular blood donation, endurance athletics, or vegetarian and vegan diets where only non-heme iron is available.

For GG individuals in these situations, the actionable steps mirror those for other TMPRSS6 iron-reducing variants: maximize dietary iron absorption through meal composition (vitamin C pairing, avoiding inhibitors), monitor serum ferritin periodically, and choose iron bisglycinate over ferrous sulfate if supplementation is needed. AA individuals can use their genetically lower hepcidin as reassurance that iron deficiency is less likely — though high-demand states can deplete anyone's stores.

Interactions

rs2235321 belongs to the same TMPRSS6 locus as the primary coding variant rs855791⁹⁹ rs855791
Ala736Val missense variant; the strongest common genetic determinant of iron status, with the A allele reducing matriptase-2 enzyme activity directly, the intronic variant rs2413450¹⁰¹⁰ rs2413450
TMPRSS6 intronic tag variant independently associated with MCV, MCH, and hemoglobin in GWAS of over 700,000 individuals, and the upstream regulatory variants rs228918 and rs228921. These variants are partially correlated through linkage disequilibrium¹¹¹¹ linkage disequilibrium
Non-random co-inheritance of alleles at nearby loci because they sit close together on the chromosome and are rarely separated by recombination in the population but capture partially distinct functional signals. In the Jallow 2021 Gambian cohort, rs2235321 showed independent hepcidin effects even when rs855791 did not — suggesting it tags a haplotype element active in African ancestry populations where the LD structure around rs855791 differs from European populations.

Carriers of multiple TMPRSS6 risk alleles across these variants may have a compounded hepcidin-elevating effect. In practice, ferritin monitoring resolves the question of whether the combined genetic architecture translates into meaningful iron depletion for a specific individual.

The luteinizing hormone/choriogonadotropin receptor (LHCGR) sits on the surface of ovarian theca cells, testicular Leydig cells, and luteinized granulosa cells, where it receives LH and hCG signals that drive ovulation, progesterone production, and testosterone synthesis. The N312S variant — a single amino acid change at position 312 from asparagine (N) to serine (S) — sits in exon 10 near a glycosylation site in the extracellular domain¹¹ near a glycosylation site in the extracellular domain
The asparagine at position 312 is a potential N-linked glycosylation sequon; replacing it with serine eliminates this site. This change alters receptor sensitivity to LH signaling, with measurable consequences for PCOS risk, ovarian reserve longevity, and IVF treatment response.

The Mechanism

LHCGR is a G protein-coupled receptor. When LH binds, the receptor activates Gs proteins, stimulating adenylyl cyclase to produce cAMP, which drives steroidogenesis and ovulation. The N312S variant changes a potential N-linked glycosylation site in the receptor's ectodomain. Asparagine (N) at position 312 can be glycosylated, while serine (S) cannot. In vitro studies of granulosa cells show that women homozygous for asparagine at both LHCGR 312 and FSHR 680 display lower cAMP activity²² In vitro studies of granulosa cells show that women homozygous for asparagine at both LHCGR 312 and FSHR 680 display lower cAMP activity
Reduced receptor signaling when both gonadotropin receptors carry the asparagine variant compared to serine homozygotes. The asparagine variant appears to create a receptor that is more sensitive to LH — requiring less LH to achieve the same downstream effect — which sounds advantageous but can dysregulate the tightly calibrated LH-FSH balance that governs normal follicular development.

The Evidence

PCOS risk. A 2012 case-control study in 198 PCOS and 187 control Sardinian women³³ A 2012 case-control study in 198 PCOS and 187 control Sardinian women
Capalbo et al. Clinical Endocrinology 2012 found that carrying at least one N allele (T on plus strand) increased PCOS risk 2-fold (OR 2.04, 95% CI 1.32–3.14, P=0.001), with NN homozygotes at 2.7-fold risk (OR 2.73, 95% CI 1.25–5.95, P=0.01). A 2015 Indian study⁴⁴ A 2015 Indian study
Thathapudi et al. Genetic Testing and Molecular Biomarkers found the SS genotype (GG on coding strand) associated with higher PCOS risk in their population (OR 3.36), elevated BMI, and higher LH/FSH ratios — though the direction of the risk allele differed from the Sardinian study, highlighting population heterogeneity. A recent meta-analysis of 10 studies (1,431 PCOS cases, 1,317 controls) found no significant overall association, suggesting the effect may be population-specific rather than universal.

Ovarian aging. A 2025 multicenter study of 1,240 Chinese women with diminished ovarian reserve or primary ovarian insufficiency⁵⁵ A 2025 multicenter study of 1,240 Chinese women with diminished ovarian reserve or primary ovarian insufficiency
Ma et al. Reproductive Biology and Endocrinology 2025 versus 72,846 controls found the TT genotype (NN) at 3.7-fold increased risk of POI (OR 3.73, 95% CI 2.09–6.67, P<0.001). Critically, TT carriers were diagnosed with POI approximately 7 years earlier (25.5 ± 6.4 years) than CC carriers (32.0 ± 5.1 years). The CT genotype (NS) also showed elevated DOR risk (OR 1.47, 95% CI 1.27–1.69). This large-scale finding positions LHCGR N312S as a potential biomarker for accelerated ovarian aging.

IVF outcomes. A prospective study of 617 IVF patients⁶⁶ A prospective study of 617 IVF patients
Lindgren et al. Human Reproduction 2016 found that LHCGR S312 carriers (C allele) had higher pregnancy rates (OR 1.61, P=0.008), and women homozygous for serine at both LHCGR and FSHR achieved dramatically higher pregnancy rates (OR 14.4, P=0.016). The follow-up study of 665 women⁷⁷ The follow-up study of 665 women
Lindgren et al. Journal of Assisted Reproduction and Genetics 2019 confirmed that women with 4 serine alleles across both receptors had a 62% cumulative live birth rate across three IVF cycles versus 43–47% for other genotypes (adjusted HR 1.89, P=0.049). Genotype-guided LH supplementation⁸⁸ Genotype-guided LH supplementation
Ramaraju et al. Frontiers in Endocrinology 2021 in 193 women showed improved pregnancy rates when LH dosing was matched to N312S genotype (P=0.049).

However, the evidence is not unanimous. A 2022 study of 1,183 patients⁹⁹ A 2022 study of 1,183 patients
Pirtea et al. Fertility and Sterility found no significant association between FSHR/LHCGR polymorphisms and oocyte yield, blastocyst rate, implantation, or live birth, concluding these variants "should not be considered reproductive predictors." This discrepancy may reflect differences in stimulation protocols, population composition, or the statistical power needed to detect interaction effects.

Practical Implications

The clinical utility of LHCGR N312S genotyping is strongest in two contexts: assessing PCOS risk and personalizing IVF protocols.

For women with TT (NN) genotype, the enhanced LH receptor sensitivity may contribute to the LH-driven androgen excess that characterizes PCOS. The 2025 Chinese study's finding of accelerated ovarian aging in TT carriers suggests this genotype warrants proactive ovarian reserve monitoring, particularly for women planning to delay childbearing.

For IVF, the interaction between LHCGR and FSHR genotypes defines a pharmacogenetic profile. Women with CC at both rs2293275 and rs6166 (SS at both receptors) appear to have an optimally responsive gonadal axis for ART, while TT carriers at LHCGR may benefit from adjusted LH supplementation protocols. The genotype-guided approach — withholding exogenous LH from NN carriers (whose receptors are already highly sensitive) and providing full-dose LH to SS carriers — showed promising results in the Ramaraju 2021 trial.

For men, LHCGR mediates LH signaling to Leydig cells for testosterone production. While specific rs2293275 data in male fertility is limited, the receptor's role in spermatogenesis makes this variant relevant to male reproductive assessment.

Interactions

FSHR rs6166 (N680S): The strongest documented interaction is with the FSH receptor N680S variant. Women homozygous for serine at both LHCGR N312S (CC genotype) and FSHR N680S (GG genotype) — the "4S" phenotype — had a 62% cumulative live birth rate across three IVF cycles versus 43–47% for other combined genotypes (adjusted HR 1.89, P=0.049). In vitro, granulosa cells from women homozygous for asparagine at both receptors showed lower cAMP activity, suggesting a combined receptor sensitivity profile. This interaction defines a pharmacogenetic subgroup: 4S women appear to respond particularly well to standard IVF protocols, while 4N women (TT at rs2293275 + AA at rs6166) may represent a distinct poor-response phenotype requiring protocol modification.

Compound implication for LHCGR TT + FSHR AA: Women carrying TT at rs2293275 and AA at rs6166 (4N phenotype) may have a combined receptor sensitivity profile that paradoxically impairs IVF response despite individually heightened receptor sensitivity. These women may benefit from modified stimulation protocols with carefully titrated gonadotropin dosing and extended monitoring. Conversely, the 4S phenotype (CC at rs2293275 + GG at rs6166) may represent the optimal pharmacogenetic profile for standard ART protocols.

Most people have never heard of TYK2, yet this kinase sits at the crossroads of three of the most clinically important cytokine pathways in autoimmune disease. TYK2¹¹ TYK2
Tyrosine kinase 2, a member of the JAK (Janus kinase) family that couples cytokine receptor signals to downstream transcription factor activation transduces signals from IL-12, IL-23, and type I interferon receptors — the same pathways targeted by modern immunology drugs and disrupted in lupus, rheumatoid arthritis, psoriasis, and type 1 diabetes. The rs2304256 (V362F) variant is a common allele that subtly shifts how TYK2 is expressed and processed, with measurable downstream protection across this disease spectrum.

Unlike the better-known TYK2 p.Pro1104Ala variant (rs34536443), which directly impairs kinase domain activity, V362F operates through a different mechanism: it promotes the inclusion of exon 8 in the mature TYK2 transcript, which is required for TYK2 to bind its cognate cytokine receptors. Carriers of the A allele show mildly enhanced TYK2 expression in whole blood — an effect that appears, paradoxically, to dampen rather than amplify net autoimmune signaling output, possibly through enhanced regulatory signaling or feedback inhibition.

The Mechanism

rs2304256 maps to exon 8 of TYK2 at chromosome 19p13.2 (GRCh38 position 10,364,976). The variant encodes a valine-to-phenylalanine substitution at residue 362 (p.Val362Phe) in the FERM (four-point-one, ezrin, radixin, moesin) domain of TYK2, which mediates receptor binding and is essential for correct cytokine receptor coupling.

Li et al. (2020)²² Li et al. (2020) demonstrated that rs2304256 — together with the intronic variant rs12720270 in intron 7 — promotes inclusion of exon 8 in TYK2 mRNA. Since exon 8 encodes part of the FERM domain required for receptor binding, its inclusion affects receptor affinity and downstream signal calibration. The A allele at rs2304256 also acts as a cis-eQTL³³ cis-eQTL
A cis-eQTL (expression quantitative trait locus) is a genetic variant that influences the expression level of a nearby gene; "cis" means the gene affected is on the same chromosome for TYK2 in whole blood, mildly increasing TYK2 transcript levels.

This mechanism is distinct from — and independent of — the pseudokinase domain variant rs34536443 (p.Pro1104Ala), which directly impairs kinase regulatory activity. The two variants affect different functional domains through different molecular mechanisms and are in weak linkage disequilibrium, meaning individuals can carry either, both, or neither protective allele.

The Evidence

The protective effects of rs2304256 are among the most replicated in TYK2 genetics. A meta-analysis by Tao et al. (2011)⁴⁴ meta-analysis by Tao et al. (2011) pooling 11 studies with 21,497 cases and 22,647 controls found the A allele confers OR 0.78 (95% CI 0.70–0.87, P<0.0001) for autoimmune and inflammatory diseases. The protection follows an additive dose-response: CA heterozygotes show OR 0.70 (P<0.0001), while AA homozygotes show OR 0.64 (P=0.003) compared to CC.

For autoimmune rheumatic diseases specifically, Lee and Bae (2016)⁵⁵ Lee and Bae (2016) analyzed 12 studies (16,335 patients / 30,065 controls) and found the A allele OR 0.885 overall, with a stronger protective effect in Caucasians (OR 0.822). For SLE in Caucasians specifically, the protection reaches OR 0.737 — a substantial 26% odds reduction that is statistically robust but absent in Asian populations, where A allele frequency is considerably higher and the genetic architecture of autoimmune risk differs.

The most striking single-disease evidence comes from type 1 diabetes. Pellenz et al. (2021)⁶⁶ Pellenz et al. (2021) demonstrated that in a Brazilian cohort, AA homozygotes had OR 0.48 (95% CI 0.29–0.81) for T1D under a recessive model — essentially halved risk — with equivalent protection under the additive model (OR 0.47, P<0.0001). The mechanism likely involves TYK2's role in interferon-driven pancreatic beta-cell apoptosis during insulitis, the early inflammatory phase preceding T1D.

A comprehensive 2021 systematic review and meta-analysis⁷⁷ 2021 systematic review and meta-analysis of 34 studies across eight autoimmune conditions confirmed rs2304256's protective association as one of the most consistently observed in TYK2 genetics, spanning MS, SLE, RA, Crohn's disease, ulcerative colitis, psoriasis, RA, and T1D.

Practical Implications

The A allele at rs2304256 is common — about 28% frequency in Europeans and 46% in East Asians — making AA homozygosity a real possibility (~8% of Europeans, ~21% of East Asians). Unlike the ultra-rare P1104A allele at rs34536443, this variant's protection is accessible to a substantial portion of the general population.

For CA and AA carriers, this result is most relevant in three contexts: (1) when being evaluated for autoimmune conditions, where it provides some baseline reassurance and may contextualize immune workup thresholds; (2) when any JAK or TYK2 inhibitor therapy is being considered, since baseline TYK2 signaling differs from the population norm; and (3) when considering family risk counseling for autoimmune diseases.

Pharmacologically, deucravacitinib (Sotyktu), the FDA-approved TYK2 pseudokinase inhibitor, operates on a different domain than V362F affects — but both influence TYK2-mediated signaling. Carriers of the A allele at rs2304256 may have subtly different baseline responses to TYK2 inhibitor therapy compared to CC homozygotes, though this has not been formally studied.

Interactions

rs2304256 is one of at least four independent protective signals in the TYK2 gene. The most studied is rs34536443 (p.Pro1104Ala), which affects the pseudokinase domain and is notably rarer (~4% in Europeans). The two variants operate through independent mechanisms (splicing/expression vs. kinase domain allostery) and are additive — carriers of the A allele at rs2304256 who also carry the C allele at rs34536443 have two distinct layers of TYK2 attenuation.

The intronic variant rs12720270 is in linkage disequilibrium with rs2304256 and acts through the same exon 8 splicing mechanism; the two variants were identified together in the same functional study. rs12720356 is a third independent protective TYK2 signal.

Beyond TYK2, the protective effect of rs2304256 acts within the broader autoimmune genetic architecture that includes PTPN22 (rs2476601), CTLA4 (rs3087243), and HLA class II loci — variants that modulate T cell activation thresholds through different mechanisms. Combined protective alleles across these loci likely confer additive reductions in autoimmune disease susceptibility, though formal compound interaction studies are limited.

TMPRSS6¹¹ TMPRSS6
Transmembrane serine protease 6, also called matriptase-2 — a liver-expressed enzyme that negatively regulates iron absorption by cleaving hemojuvelin from the hepatocyte surface, thereby suppressing hepcidin production sits at the centre of the body's iron-sensing machinery. Its most studied variant — Ala736Val (rs855791) — is the single strongest common genetic determinant of iron status. rs2413450 is a second, independent marker at the same locus: an intronic variant located approximately 426 nucleotides downstream of exon 14 in the TMPRSS6 transcript. It does not itself change the protein sequence, but its alleles tag functional variation in TMPRSS6 expression or splicing regulation, and it has been independently replicated in GWAS for red blood cell traits.

The Mechanism

Because rs2413450 is intronic, it does not directly alter the matriptase-2 protein. Instead, it acts as a regulatory tag variant²² regulatory tag variant
A non-coding variant in linkage disequilibrium with nearby functional variants, or one that directly affects intronic splicing enhancer/silencer sequences or gene expression levels. The T allele at rs2413450 is associated with lower matriptase-2 activity, either through altered splicing efficiency or by tagging a haplotype that carries reduced-function regulatory elements. Less active matriptase-2 means less cleavage of hemojuvelin³³ hemojuvelin
A co-receptor of BMP receptors on hepatocyte surfaces that amplifies BMP/SMAD signalling and thereby drives hepcidin transcription, which in turn raises hepcidin. Higher hepcidin degrades ferroportin⁴⁴ ferroportin
The only known iron exporter on the basolateral surface of duodenal enterocytes and macrophages — hepcidin binding triggers its internalization and degradation, blocking iron release into the bloodstream on gut enterocytes, limiting iron entry into the circulation. The net result is the same as for the coding variant rs855791: smaller red blood cells (lower MCV), less hemoglobin per cell (lower MCH), and modestly reduced hemoglobin concentration.

The Evidence

The association was first reported in the landmark CHARGE Consortium GWAS⁵⁵ CHARGE Consortium GWAS
Ganesh SK et al. Multiple loci influence erythrocyte phenotypes in the CHARGE Consortium. Nat Genet, 2009, which studied 24,167 Europeans and confirmed rs2413450 associated with MCV (P = 3 × 10⁻⁴¹), MCH (P = 9 × 10⁻³⁴), and hematocrit (P = 2 × 10⁻¹³) — effect sizes comparable to the primary TMPRSS6 missense variant.

A large trans-ethnic meta-analysis Chen et al.⁶⁶ Chen et al.
Chen MH et al. Trans-ethnic and Ancestry-Specific Blood-Cell Genetics in 746,667 Individuals from 5 Global Populations. Cell, 2020 confirmed the T allele reduces MCH by 0.126 standard deviations (P = 5 × 10⁻¹⁶) across European, East Asian, African, South Asian, and Latino populations, establishing this as a robust multi-ethnic signal.

In African-ancestry cohorts⁷⁷ African-ancestry cohorts
Gichohi-Wainaina WN et al. Associations between Common Variants in Iron-Related Genes with Haematological Traits in Populations of African Ancestry. PLoS One, 2016, rs2413450 T carriers showed a 0.19 g/dL reduction in hemoglobin (P = 0.02), one of only four TMPRSS6 variants that successfully replicated European GWAS signals in African populations — suggesting the functional variant it tags is ancestrally shared rather than population-specific.

A Turkish case-control study Batar et al.⁸⁸ Batar et al.
Batar B et al. The role of TMPRSS6 gene variants in iron-related hematological parameters in Turkish patients with iron deficiency anemia. Gene, 2018 found that rs2413450 was associated with elevated total iron-binding capacity in IDA patients — a marker of iron-starved erythropoiesis — consistent with the GWAS direction.

The evidence level is rated strong: the association has been replicated in multiple independent cohorts spanning diverse ancestries and total sample sizes exceeding 700,000 individuals. Effect sizes are modest (fractions of a standard deviation per allele) but robust.

Practical Implications

Carrying one or two copies of the T allele does not cause iron deficiency on its own. The effect is sub-clinical under conditions of adequate dietary iron. But when iron demand rises — during heavy menstrual cycles, pregnancy, vegetarian or vegan eating, endurance athletics, or blood donation — T carriers have a narrower margin before iron stores drop into deficiency range.

The most actionable step is knowing your ferritin level. Serum ferritin below 30 µg/L indicates depleted stores even when hemoglobin is still within range; below 12 µg/L is overt deficiency. If stores are adequate, standard dietary guidance applies. If stores trend low, dietary strategies to maximize absorption become important: pairing iron-rich foods with vitamin C, avoiding tea and coffee within an hour of iron-containing meals, and choosing iron bisglycinate⁹⁹ iron bisglycinate
A chelated form absorbed via peptide transporters, partially bypassing hepcidin-controlled ferroportin, and better tolerated than ferrous sulfate in sensitive individuals over ferrous sulfate if supplementing.

Interactions

This variant operates through the same hepcidin pathway as the primary TMPRSS6 missense variant rs855791. Carrying the T allele at rs2413450 in addition to the A allele at rs855791 may compound the iron-reducing effect, since both tag haplotypes with reduced matriptase-2 function — though the two variants are not in perfect linkage disequilibrium and capture partially overlapping and partially independent variance.

Interaction with HFE variants (rs1800562 C282Y, rs1799945 H63D) is the most clinically relevant context: HFE loss-of-function raises hepcidin sensitivity and causes iron overload, while TMPRSS6 T alleles raise hepcidin and limit absorption. In someone with borderline HFE heterozygosity, TMPRSS6 T alleles may actually attenuate iron accumulation. In someone with purely nutritional iron deficiency risk, no HFE context is needed — the TMPRSS6 effect stands alone.

Every cell in your body constantly displays a sample of its internal protein inventory on its surface, using molecules of the MHC class I system¹¹ MHC class I system
Major Histocompatibility Complex class I proteins (HLA-A, HLA-B, HLA-C) that present 8-10 amino acid peptides to patrolling CD8+ T cells for immune surveillance as display platforms. Before a peptide can be loaded, it must first be trimmed to the right length inside the endoplasmic reticulum²² endoplasmic reticulum
the cellular compartment where protein folding and quality control occur, and where peptides destined for HLA class I presentation are processed. ERAP1 (Endoplasmic Reticulum Aminopeptidase 1) is the enzyme that performs this trimming — clipping amino acids from the N-terminus of longer precursor peptides until an optimal 8-10-mer is generated. The rs26653 variant subtly modifies the ERAP1 protein at position 127, and the resulting shift in trimming behavior has documented consequences for risk of psoriasis and ankylosing spondylitis.

The Mechanism

rs26653 is a missense variant (c.380G>C in coding notation) that substitutes a proline for an arginine at amino acid position 127 of ERAP1 (p.Arg127Pro). Position 127 sits in an N-terminal regulatory domain of the enzyme, outside the catalytic site and peptide-binding pocket. Structural and biochemical analyses suggest that the proline substitution reduces conformational flexibility at this position³³ proline substitution reduces conformational flexibility at this position
proline is a cyclic amino acid that restricts the backbone dihedral angles available to a peptide chain, potentially affecting interdomain motion and allosteric transitions in the enzyme, consistent with the observation that ERAP1 allotypes carrying Pro127 tend to have modestly lower catalytic activity overall, though no single in vitro study has isolated the effect of this variant alone.

The clinical significance of rs26653 arises not from a dramatic loss of enzymatic activity, but from subtle shifts in the peptide repertoire ultimately loaded onto MHC class I molecules. In individuals who carry the immune-sensitizing HLA alleles HLA-C*06:02 (associated with psoriasis) or HLA-B27 (associated with ankylosing spondylitis), even small changes in which peptides are generated and in what abundance can tip the balance toward aberrant self-recognition. The ERAP1 locus has now been shown to interact [epistatically | a situation where the clinical effect of one gene depends on the genotype at a second, separate locus] with both HLA-C*06:02 and HLA-B27, meaning that rs26653's disease risk operates primarily through — and is amplified by — specific HLA backgrounds.

The Evidence

Psoriasis: Age-stratified signal. A large Swedish psoriasis cohort study first highlighted rs26653 as an independently significant ERAP1 variant, distinct from the previously characterized rs27524 and rs30187. This study⁴⁴ This study
Lysell et al. Genetic association with ERAP1 in psoriasis is confined to disease onset after puberty and not dependent on HLA-C*06. J Invest Dermatol, 2013 found that rs26653 was associated with psoriasis overall (OR=1.31, 95% CI 1.16–1.48), but the association was dramatically concentrated in individuals whose psoriasis appeared between ages 10 and 20 (OR=1.59, 95% CI 1.28–1.98, P=0.00008). Prepubertal onset (ages 0–9) lacked association, as did late-onset disease (>40 years). Importantly, the association was not modulated by HLA-C*06:02 status — making rs26653's age-specific effect mechanistically distinct from rs27524's HLA-C*06:02-dependent effect.

A Chinese case-control study found a similar signal for psoriasis vulgaris: Pro127 homozygotes had nearly double the risk of psoriasis⁵⁵ Pro127 homozygotes had nearly double the risk of psoriasis
OR=1.96 for CC vs GG; C allele OR=1.40, P=0.042; stronger in early-onset subgroup (OR=2.08, P=0.036).

Ankylosing spondylitis: HLA-B27-conditioned epistasis. The original landmark discovery of ERAP1's role in AS came from a genome-wide study demonstrating that ERAP1 variants affect AS risk exclusively in HLA-B27-positive individuals. Evans et al.⁶⁶ Evans et al.
Interaction between ERAP1 and HLA-B27 in ankylosing spondylitis implicates peptide handling in the mechanism for HLA-B27 in disease susceptibility. Nat Genet, 2011 reported a combined interaction P-value of 7.3×10⁻⁶, with no detectable ERAP1 effect in HLA-B27-negative individuals. A Turkish population study found that rs26653 specifically was associated with AS susceptibility (OR=1.609, 95% CI 1.163–2.226, p=0.004), with a population-attributable risk of 23.4%, though notably no stratification by HLA-B27 status revealed a significant interaction in that smaller cohort.

A meta-analysis pooling 24,271 AS patients and 42,666 controls found that rs26653's AS association was population-specific: statistically significant in Caucasian populations, not significant in Asians, which contributed to the overall pooled OR (1.15, 95% CI 0.94–1.42) crossing the null.

Functional context. In biochemical studies examining ERAP1 allotypes, Pro127-containing allotypes show modestly lower rates of substrate processing compared to Arg127-containing allotypes in some contexts. Studies ranking ERAP1 polymorphisms' contribution to HLA-B27 peptidome shaping⁷⁷ Studies ranking ERAP1 polymorphisms' contribution to HLA-B27 peptidome shaping
Kochan et al., PMC6030728 note that prior in vitro work found no isolated effect of R127P on trimming — the functional consequences of rs26653 may be context-dependent, emerging primarily within specific allotype combinations or HLA environments rather than in isolation.

Practical Implications

Carrying one or two copies of the G allele (Pro127) means your ERAP1 enzyme trimming landscape is subtly shifted. The most clinically relevant implication depends on your HLA background:

For psoriasis risk, the association is strongest if your skin condition appeared or appears in adolescence (ages 10–20) — rs26653 may be a contributing factor even in the absence of HLA-C*06:02. For ankylosing spondylitis, the ERAP1 locus primarily matters if you are HLA-B27 positive. If you carry both HLA-B27 and ERAP1 risk variants, your AS risk is substantially higher than either factor alone.

Both conditions are chronic and manageable with early recognition. For psoriasis, prompt treatment prevents skin thickening and joint involvement. For ankylosing spondylitis — inflammatory back pain that is classically worse in the morning, improves with activity, and comes on before age 45 — early diagnosis and treatment with NSAIDs or biologics dramatically reduces the risk of permanent spinal fusion.

Interactions

rs26653 × HLA-C*06:02 (rs12191877): Partially independent in psoriasis. Unlike rs27524, which shows strict dependence on HLA-C*06:02 for its psoriasis effect, rs26653's age-stratified psoriasis signal is not abolished in HLA-C*06:02-negative individuals. This suggests rs26653 may influence a broader set of peptide/HLA interactions, or that adolescent-onset psoriasis involves different immunological substrates than adult-onset plaque psoriasis.

rs26653 × HLA-B27: Epistasis in ankylosing spondylitis. The ERAP1 locus broadly interacts with HLA-B27 in AS pathogenesis. The mechanism is mechanistic necessity⁸⁸ The mechanism is mechanistic necessity
ERAP1 trims peptides that are then loaded onto HLA-B27; altered trimming changes which self-peptides are presented, potentially generating arthritogenic peptides or increasing free heavy chain formation. Compound risk in HLA-B27-positive individuals carrying multiple ERAP1 risk alleles (including rs26653 + rs30187) is documented.

rs26653 × rs30187 (ERAP1 Lys528Arg): Same-gene haplotype effects. rs26653 and rs30187 are both missense variants in ERAP1 and travel together on haplotypes. The protective haplotype (rs30187/rs26618/rs26653 with alleles C-T-G, where G = Arg127 coding-strand notation) is associated with reduced AS risk (OR=0.77). This means the combination of Arg127 (rs26653) and Lys528 (rs30187) residues in the same ERAP1 protein defines a high-risk allotype, while Arg528 (rs30187 protective variant) tends to reduce trimming activity regardless of rs26653 status.

The interaction between rs26653 and rs30187 is a strong candidate for a compound action: individuals carrying risk alleles at both sites have a different ERAP1 allotype with distinct immunopeptidome characteristics compared to those with mixed or protective allotypes at both sites.